Testosterone Cypionate vs Undecanoate: Pharmacokinetics, Injection Protocol, and Blood Test Timing

Testosterone cypionate (Test C) and injectable testosterone undecanoate (brand names Nebido in Europe and Australia, Aveed in the United States) are both intramuscular TRT formulations. While they share the same therapeutic goal, they differ substantially in pharmacokinetics, practical management, and the challenges they present for blood test monitoring.

Testosterone cypionate has a half-life of approximately 5 to 7 days and is the standard TRT formulation in the United States. It is injected weekly or twice-weekly and reaches stable serum levels within 3 to 5 weeks. Its pharmacokinetics are well-characterised, predictable, and straightforward to monitor.

Injectable testosterone undecanoate has a half-life of approximately 20 to 21 days. It is designed to provide sustained testosterone release over a 10 to 14 week interval, dramatically reducing injection frequency. The trade-off is a prolonged and variable loading period, limited ability to adjust dose, and blood test interpretation that is highly dependent on where in the long injection cycle the draw occurs.

This comparison focuses on injectable testosterone undecanoate. Oral testosterone undecanoate (Andriol, Jatenzo) has an entirely different profile and is not covered here.

Ester chain length and half-life:

• Cypionate: 8-carbon ester, half-life approximately 5 to 7 days
• Undecanoate: 11-carbon ester, half-life approximately 20 to 21 days
• Undecanoate is approximately 3 to 4 times longer-acting than cypionate

Peak serum levels:

• Cypionate: peaks at approximately 4 to 5 days post-injection. The later peak (compared to enanthate) produces a very slightly more sustained early rise.
• Undecanoate: peaks at approximately 7 days post-injection (range 3 to 14 days), reflecting the slow depot release of the large-volume, high-concentration oil formulation.

Injection frequency:

• Cypionate: weekly or twice-weekly for TRT (52 to 104 injections per year)
• Undecanoate: loading injections at week 0 and week 6, then every 10 to 14 weeks for maintenance (4 to 5 injections per year)

Steady-state timeline:

• Cypionate: reaches steady state in approximately 3 to 5 weeks
• Undecanoate: requires approximately 30 weeks to reach true pharmacokinetic steady state (5 half-lives of 20 to 21 days). The loading protocol (injections at week 0 and week 6) accelerates the approach to therapeutic levels, but serum testosterone remains variable for months.

Injection logistics:

• Cypionate: standard 0.5 to 2 mL injection, intramuscular or subcutaneous, flexible injection sites, can be self-administered easily
• Undecanoate: 4 mL (1,000 mg) intramuscular injection only, slow administration required (minimum 2 minutes), large injection volume limits site selection, and in the US the Aveed REMS program means many patients receive the injection at the prescribing clinic rather than self-administering

Blood draw timing for accurate readings:

• Cypionate: draw at trough, immediately before the next scheduled injection. On a weekly protocol, this is day 7; on twice-weekly, it is day 3.5. The trough is stable, reproducible, and the gold standard for safety monitoring.
• Undecanoate: two reference points are used clinically. The mid-point draw (approximately week 6 of a 12-week interval) reflects average levels and is most useful for assessing overall adequacy. The trough draw (immediately before the next injection at week 10 to 14) reflects the nadir and helps determine if the inter-injection interval needs shortening. Every blood draw for undecanoate must document the exact date and time of the last injection.

Aromatisation and oestrogen management:

• Cypionate: oestradiol tracks the weekly injection cycle. Aromatase inhibitors (if needed) can be dosed consistently on a weekly or twice-weekly basis.
• Undecanoate: oestradiol follows the slow, broad release curve. Acute oestrogen spikes are less common, but oestrogen management over a 10 to 14 week interval is complex. Most clinicians avoid routine aromatase inhibitor use in undecanoate patients and instead manage dose or interval.

Dose adjustment:

• Cypionate: immediate dose adjustment at the next injection. Effects apparent within 1 to 2 weeks.
• Undecanoate: adjustment is made by changing the inter-injection interval (shorter for higher average levels, longer for lower). Full effect of any change requires multiple additional injection cycles to be apparent.

Choose testosterone cypionate for:

• Standard TRT in the United States: it is the most prescribed formulation, widely available, and the default on most formularies
• Patients who need dose flexibility: adjustments take effect within weeks, not months
• Blood work monitoring that is straightforward and comparable across visits
• Any use case where the protocol may change (dose titration, cycling, planned discontinuation)
• Patients comfortable with weekly or twice-weekly self-injection

Choose testosterone undecanoate for:

• Patients with significant needle phobia or compliance issues with frequent injections
• Patients managed in a clinic setting where injections are administered by healthcare staff
• Patients in countries where Nebido is the standard formulary option and cypionate is not available
• Patients who have achieved stable levels on undecanoate and prefer the quarterly schedule

Blood test timing implications:

• Cypionate patients should present for blood work on day 7 of a weekly protocol or day 3.5 of a twice-weekly protocol, before the next injection. The same day in the cycle should be used at every visit.
• Undecanoate patients must communicate the exact date of their last injection to the laboratory and their clinician. Without this, results cannot be meaningfully interpreted. Consider keeping a log of injection dates and bringing it to every blood draw.

When undecanoate is clearly not appropriate:

• Performance enhancement cycling: no flexibility, no PCT compatibility
• Any situation requiring rapid dose adjustment or quick discontinuation
• Patients who want tight control over oestradiol levels